IP Verse

N-Acetyl Cysteine Compositions And Methods To Improved The Therapeutic Efficacy Of Acetaminophen - EP2453743

The patent EP2453743 was granted to The Board OF Trustees OF The Leland Stanford Junior University on Apr 12, 2017. The application was originally filed on Jul 15, 2010 under application number EP10800558A. The patent is currently recorded with a legal status of "Revoked".

EP2453743

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Application Number
EP10800558A
Filing Date
Jul 15, 2010
Status
Revoked
May 5, 2023
Grant Date
Apr 12, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PRUFER & PARTNER MBBJan 12, 2018PRUFER & PARTNER MBB PATENTANWALTE RECHTSANWALTE -

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2008139654
INTERNATIONAL-SEARCH-REPORTUS2008226715
OPPOSITIONDE29707005U
OPPOSITIONUS2002142991
OPPOSITIONUS2008139654
OPPOSITIONUS5474757
OPPOSITIONWO0168069
OTHERUS2002142991
SEARCHUS2002142991
SEARCHUS2008139654

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY OF EASTON-
EXAMINATION- Levine's pharmacology drug actions and reactions, pages 213 - 213-
OPPOSITION- ANDRUS et al., "Effects of legislation restricting pack sizes of paracetamol on self poisoning", BMJ, (20010000), vol. 323, page 633, XP055277864-
OPPOSITION- ARONSON, Side effects of Drugs Annual 26, (20030000), pages 113 - 115, XP055453109-
OPPOSITION- BENNETT et al., Clinical Pharmacology, (20080000), pages 258 - 260, XP055453100-
OPPOSITION- "Braintree", Physicians' Desk Reference, (20000000), pages 812 - 813, XP055453097-
OPPOSITION- "Fluimucil complex 500 mg / 200 mg comprimidos efervescentes", botplusweb.portalfarma.com, (20180102), URL: https://botplusweb.portalfarma.com/botplus.aspx, XP055453074-
OPPOSITION- "Fluimucil complex 500 mg / 200 mg comprimidos efervescentes", Technical data sheet, (20071200), XP055453046-
OPPOSITION- Hawton K et al, "Popular analgesic combo withdrawn in UK because of overdose risk, Medscape", Medscape medical News, (20050221), XP055453106-
OPPOSITION- LALL et al., "Paracetamol Poisoning in Children, Symposium: Toxicology and Poisoning-II", Indian J Pediatr, (19980000), vol. 65, pages 393 - 400, XP055453084-
OPPOSITION- NEUVONEN et al., "Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity", Int. J. Clin. Pharmacol. Ther. Toxicol., (19850900), vol. 23, no. 9, pages 497 - 500, XP055453131-
OPPOSITION- "User's Information", Fluimucil complex 500 mg / 200 mg comprimidos efervescentes, (20071200), XP055453055-
OPPOSITION- PARCELL, "Biochemical and Nutritional Influences on Pain", Contemporary Pain Medicine, (20080000), pages 133 - 172, XP055453127
OPPOSITION- ALTMAN et al., "Three-month efficacy and safety of acetaminophen extended- release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study", Osteoarthritis and Cartilage, (20070000), vol. 15, no. 4, pages 454 - 461, XP005921002
OPPOSITION- PEREZ et al., "The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study", Pain, (20030000), vol. 102, no. 3, pages 297 - 307, XP055204996
OPPOSITION- BESSEMS et al., "Paracetamol (Acetaminophen)-Induced Toxicity: Molecular and Biochemical Mechanisms , Analogues and Protective Approaches", Critical Reviews in Toxicology, vol. 31, no. 1, pages 55 - 138, XP055389072
OTHER- "Dosing chart", PHYSICIANS' DESK REFERENCE (PDR.net, (20050000), page 1951-
SEARCH- "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm", (20071226), pages 1 - 4, URL: http://www.clinicaltrials.gov/ct2/show/record/NCT00585559?term=paracetamol+and+acetyl+cysteine&rank=2, (20121109), XP055043637 [X] 1-5,9-13 * the whole document *-
SEARCH[ ] - IVERSEN H K, "N ACETYLCYSTEINE ENHANCES NITROGLYCERIN-INDUCED HEADACHE AND CRANIAL ARTERIAL RESPONSES", CLINICAL PHARMACOLOGY AND THERAPEUTICS, (1992), vol. 52, no. 2, ISSN 0009-9236, pages 125 - 133-
SEARCH- IVERSEN H K, "N ACETYLCYSTEINE ENHANCES NITROGLYCERIN-INDUCED HEADACHE AND CRANIAL ARTERIAL RESPONSES", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1992), Database accession no. PREV199294126913, XP002686850 [A] 1-16 * abstract *
SEARCH- SA'ED H. ZYOUD ET AL, "N-acetylcysteine-induced headache in hospitalized patients with acute acetaminophen overdose", FUNDAMENTAL & CLINICAL PHARMACOLOGY, (20110601), vol. 25, no. 3, doi:10.1111/j.1472-8206.2010.00831.x, ISSN 0767-3981, pages 405 - 410, XP055043698 [T] * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents